Honghui Chen

Honghui Chen

Auto-generated profile, based on publicly available information

Honghui Chen

Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Guangdong Provincial Key Laboratory of Organ Medicine, Guangzhou 510080, China; Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation), Guangzhou 510080, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
QZQiang Zhao
Qiang Zhao
XWXiaobo Wang
Xiaobo Wang
KLKunpeng Liu
Kunpeng Liu
HCHonghui Chen
Honghui Chen
JDJia Dan
Jia Dan
XHXiaoshun He
Xiaoshun He
The shortage of transplant organs remains a severe global issue. Normothermic machine perfusion (NMP) has the potential to increase organ availability, yet its efficacy is hampered by the inflammatory response during machine perfusion. Mouse liver IRI models, discarded human liver models, and porcine marginal liver transplantation models were utilized to investigate whether FXR activation could mitigate inflammation-induced liver damage. FXR expression levels before and after reperfusion were measured. Gene editing and co-immunoprecipitation techniques were employed to explore the regulatory mechanism of FXR in inflammation inhibition. The expression of FXR correlates with the extent of liver damage after reperfusion. Activation of FXR significantly suppressed the inflammatory response triggered by IRI, diminished the release of pro-inflammatory cytokines, and improve liver function recovery during NMP, assisting discarded human livers to reach transplant standards. Mechanistically, FXR disrupts the interaction between p65 and p300, thus inhibiting modulating the nuclear factor kappa-B (NF-κB) signaling pathway, a key instigator of inflammation. Our research across multiple species confirms that activating FXR can optimize NMP by attenuating IRI-related liver damage, thereby improving the utilization of marginal livers for transplantation.

11 September 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
YTYunhua Tang
Yunhua Tang
JLJIahao LI
JIahao LI
MQMeiting Qin
Meiting Qin
ZLZhiying Liu
Zhiying Liu
JKJun Kang
Jun Kang
QZQiang Zhao
Qiang Zhao
Acute-on-chronic liver failure (ACLF) is a life-threatening condition with high mortality. Ischemia-free liver transplantation (IFLT), a novel clinical approach avoiding ischemia-reperfusion injury, may offer significant benefits for ACLF patients. This study included 30 ACLF patients undergoing IFLT and 97 ACLF patients undergoing conventional liver transplantation (CLT). After propensity score matching (PSM), the IFLT group comprised 28 patients, while the CLT group had 51 patients. In the PSM cohort, Kaplan-Meier analysis confirmed IFLT improved patient and graft survival for ACLF patients (log rank P=0.018 and 0.018, respectively). The IFLT group demonstrated better six-month patient survival rates (100% vs 74.5%, P=0.009) and lower post-reperfusion syndrome, shorter operative time, reduced intraoperative blood loss, less blood products use. Furthermore, ACLF patients receiving IFLT experienced fewer early allograft dysfunction, reduced intensive care unit stays, earlier extubation, faster consciousness recovery, shorter time to first flatus. Accelerated recovery of liver, circulatory, respiratory, coagulation functions were observed in the IFLT group, along with fewer acute kidney injury. Notably, ACLF patients receiving ECD livers in the IFLT group achieved better survival and clinical outcomes. Consequently, IFLT enhanced the survival rates and promoted the recovery of remote organs in ACLF patients, and improved clinical prognoses for those receiving ECD livers.